TOFFOLI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 4.629
EU - Europa 3.089
AS - Asia 2.588
SA - Sud America 360
Continente sconosciuto - Info sul continente non disponibili 282
AF - Africa 127
OC - Oceania 14
Totale 11.089
Nazione #
US - Stati Uniti d'America 4.489
SG - Singapore 848
PL - Polonia 843
IT - Italia 720
CN - Cina 524
VN - Vietnam 358
DE - Germania 276
BR - Brasile 274
SE - Svezia 269
HK - Hong Kong 226
FR - Francia 168
FI - Finlandia 135
GB - Regno Unito 127
BD - Bangladesh 116
KR - Corea 108
NL - Olanda 105
RU - Federazione Russa 99
IN - India 98
CA - Canada 80
UA - Ucraina 63
BG - Bulgaria 58
JP - Giappone 52
IE - Irlanda 51
TR - Turchia 44
MA - Marocco 42
PK - Pakistan 35
MX - Messico 31
ZA - Sudafrica 27
BE - Belgio 26
IR - Iran 26
AR - Argentina 25
ES - Italia 24
CH - Svizzera 23
AT - Austria 20
IQ - Iraq 20
SN - Senegal 19
ID - Indonesia 16
PH - Filippine 15
VE - Venezuela 15
AU - Australia 14
EC - Ecuador 13
CO - Colombia 11
CZ - Repubblica Ceca 11
RO - Romania 11
LB - Libano 10
SA - Arabia Saudita 10
TH - Thailandia 10
EG - Egitto 9
MY - Malesia 9
PT - Portogallo 9
CL - Cile 8
DK - Danimarca 8
JO - Giordania 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
PR - Porto Rico 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
TW - Taiwan 6
BO - Bolivia 5
HU - Ungheria 5
JM - Giamaica 5
KZ - Kazakistan 5
PY - Paraguay 5
RS - Serbia 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
GR - Grecia 4
LK - Sri Lanka 4
LT - Lituania 4
SY - Repubblica araba siriana 4
AZ - Azerbaigian 3
ET - Etiopia 3
HR - Croazia 3
KE - Kenya 3
NO - Norvegia 3
NP - Nepal 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
BZ - Belize 2
CG - Congo 2
CR - Costa Rica 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
MU - Mauritius 2
MZ - Mozambico 2
OM - Oman 2
PE - Perù 2
QA - Qatar 2
SI - Slovenia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
Totale 10.788
Città #
Warsaw 794
Ashburn 652
Singapore 529
Chandler 357
Fairfield 295
San Jose 274
Hong Kong 205
Woodbridge 200
Trieste 199
Houston 164
Dallas 158
Munich 152
Ann Arbor 146
Seattle 142
Council Bluffs 136
Wilmington 126
Cambridge 110
Beijing 108
Los Angeles 105
Seoul 99
Ho Chi Minh City 97
Helsinki 91
Hanoi 78
Princeton 76
Jacksonville 67
Chicago 65
Santa Clara 64
Boardman 61
Hefei 61
Sofia 58
Columbus 57
New York 55
Lauterbourg 53
Dublin 46
Milan 44
Frankfurt am Main 41
The Dalles 39
Moscow 38
Redmond 37
Rome 37
Zgierz 37
Tokyo 35
Casablanca 32
London 31
Phoenix 31
Dearborn 29
Buffalo 28
São Paulo 28
Dong Ket 26
Izmir 26
Shanghai 25
Toronto 24
Brussels 23
Dakar 19
Guangzhou 19
Atlanta 18
Denver 18
Düsseldorf 18
Amsterdam 17
Da Nang 17
Genoa 17
Orem 17
Lahore 16
Vienna 16
Chennai 15
Montreal 15
Turku 15
San Francisco 14
Brooklyn 13
Bern 12
Falls Church 12
Johannesburg 12
Stockholm 12
Haiphong 11
Manchester 11
Washington 11
Des Moines 10
Nuremberg 10
Paris 10
San Diego 10
Turin 10
Vancouver 10
Venezia 10
Boydton 9
Hải Dương 9
Mexico City 9
Zhengzhou 9
Andover 8
Bologna 8
Brno 8
Hillsboro 8
Kunming 8
Portsmouth 8
Quito 8
Redondo Beach 8
Sydney 8
Thái Nguyên 8
Venice 8
Amman 7
Boston 7
Totale 7.044
Nome #
DNA Nanotechnology for Cancer Therapy 600
Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants 517
Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: Variables affecting specificity and effectiveness 483
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia 427
Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin 380
Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy 350
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. 324
Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment 294
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 294
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 287
Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy 285
A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study 280
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity 274
A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine 264
Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples 263
Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albumin 241
Common mutations in immunoglobulin VK3 light chain sequences from B-cells of HCV-related disorders 233
Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations 221
Biocompatible tailored zirconia mesoporous nanoparticles with high surface area for theranostic applications 214
Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: A first insight 210
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine 209
Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models 205
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target 204
A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State 192
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 189
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 189
Differential proteomic analysis of hepatocellular carcinoma 188
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy 186
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma 179
A novel epigenetic machine learning model to define risk of progression for hepatocellular carcinoma patients 178
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model 174
An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma 169
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 165
New insight into therapies targeting angiogenesis in hepatocellular carcinoma 165
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies 164
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells. 162
Zebrafish: A Useful Animal Model for the Characterization of Drug-Loaded Polymeric NPs 160
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 154
Stealth-Engineered Albumin-Coated Nanoparticles for Targeted Therapy: Effective Drug Delivery and Tumor Suppression in Xenograft-Zebrafish Model 152
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma 149
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 149
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 133
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies 130
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma 126
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer 124
Oral Administration of Cancer Vaccines: Challenges and Future Perspectives 106
Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients 106
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies 103
Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients 94
Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles 27
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models 17
Totale 11.089
Categoria #
all - tutte 31.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.235


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022564 0 0 41 21 9 96 41 12 68 47 29 200
2022/20231.230 94 160 110 151 98 172 48 116 137 60 57 27
2023/2024647 38 35 36 56 45 67 102 151 7 19 60 31
2024/20251.722 39 52 96 146 145 169 139 124 202 223 216 171
2025/20263.848 451 133 357 351 350 292 513 111 399 501 214 176
2026/2027385 125 166 94 0 0 0 0 0 0 0 0 0
Totale 11.089